TNF and rheumatoid arthritis: Using a large US claims database from 2004–2010, Johnston et al. showed different results: they reported that in RA patients switching from anti-TNFα agents to another biological agent, the risk of severe infection was higher for infliximab, abatacept, adalimumab, and etanercept compared with rituximab [42].